Navigation Links
TechniScan Announces Adding Another Center to Worldwide Clinical Trials for New Breast Imaging System
Date:6/16/2010

SALT LAKE CITY, June 16 /PRNewswire-FirstCall/ -- TechniScan, (OTC Bulletin Board: TSNI) a medical device company engaged in the development and commercialization of an automated 3D breast ultrasound imaging system, today announced that it has launched a clinical study in Rochester, Minn., its third new clinical site to commence in the last five months.

TechniScan's Warm Bath Ultrasound (WBU) system is designed to capture three-dimensional images of the breast as a woman lies prone on a table and state-of-the-art ultrasound technology is used in a warm water tank to image the breast anatomy. Its revolutionary new method of imaging produces information and whole breast images that are not available with traditional reflection ultrasound or whole breast ultrasound systems presently on the market.

To date, TechniScan has scanned over 800 women in clinical studies in Salt Lake City and Ogden, Utah as well as Orange and San Diego, California. These past clinical studies focused on key factors like image quality, repeatability, and establishing protocols for testing baseline values for positive and negative predictive capabilities of the system.

According to Dr. John Klock, TechniScan's chief medical officer, the most recently completed clinical work continues to support that refraction-corrected reflection images highlight connective tissue features within the breast, whereas the speed-of-sound images show fibroglandular, ductal and terminal lobular units with high resolution.  

Image consistency and reproducibility, whether it is weeks, months or a year between exams, are critical to support precise and reliable assessment of breast lesions. Clinical studies in San Diego recently evaluated the ability of the system to reliably reproduce images from the same woman.

"We have clearly demonstrated that the system can reliably reproduce images based on reflection and sound transmission and that those images will have significant clinical utility," said David Robinson TechniScan's president and CEO.

"Volumetric whole-breast imaging provides a substantial practical advantage over conventional very-small-field-of-view sonography. We are greatly aided by the ability to produce repeatable whole-breast comparisons – left to right and present to past. These comparisons are the nuts and bolts of breast imaging, by any modality," said Michael Andre, Ph.D., adjunct professor of radiology and director of medical physics at University of California, San Diego School of Medicine.

Building on this prior clinical work, the current clinical studies in Freiberg, Germany, San Diego and Rochester will involve at least 500 women with various types of breast lesions.  Major objectives of the 12-month study will be to compare WBU to conventional breast sonography and MRI as well as to examine the WBU system's ability to differentiate between normal, benign and malignant breast tissue. These clinical studies in the U.S. are funded by a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute.

TechniScan's current study sites include the University Medical Center Freiburg in Germany, Moores UCSD Cancer Center, and the latest clinical study site in Rochester, Minnesota as well as limited imaging studies that support product development in Genoa, Italy and Salt Lake City, Utah.

"Overall we expect to image another 600 or more patients in our clinical program over the next 6-12 months," said Robinson. "These studies will provide us with critical information about the clinical utility and application of the WBU capabilities."

"The feedback that we are receiving from our scientists and radiologists at our study sites gives us good reasons to remain cautiously optimistic," said Klock.

Researchers involved in the studies will also utilize TechniScan's groundbreaking imaging network, which provides them with the ability to archive, store, and retrieve WBU images and relevant medical records and to collaborate with other research sites.  

"Our vision is to begin to create a database of thousands of breast images as well as the underlying and related image data," said Robinson. "With complete anonymity, women can contribute their mammograms, breast MRI's and WBU images along with related pathology and other information to provide researchers around the world an unprecedented opportunity to study breast cancer. TechniScan's imaging network will also allow timely and efficient collaboration of patient's records for her medical team's use. The concept is simple, yet revolutionary within the medical system and represents a key competitive advantage of the TechniScan system."

About TechniScan

TechniScan, Inc. is a medical device company engaged in the development and commercialization of a non-invasive imaging tool designed to provide physicians with automated ultrasound images of the human breast. TechniScan's WBU imaging device is limited by U.S. law to investigational use unless, and until, cleared by the FDA. For more information, please visit www.techniscanmedical.com.

Forward Looking Statements

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate, "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "potential," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of TechniScan, Inc. (the "Company") to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov, including the Company's Annual Report on Form 10-K filed on March 22, 2010. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Press Contact: Tracy Harden, TechniScan Medical Systems, (801) 994-2968, tharden@tsni.com


'/>"/>
SOURCE TechniScan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Patent Awarded to the Design of TechniScans Unique 3-D Breast Imaging System
2. TechniScan Launches 3-D Breast Ultrasound Clinical Study in Freiburg University
3. TechniScan Cofounder to Speak at SPIE Medical Imaging Conference About Ground-Breaking Science Behind the Companys Ultrasound Technology
4. In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors
5. Miltenyi Biotec Announces Release of Viscover(TM) Preclinical Contrast Agents for in vivo Small Animal Imaging
6. Epocal Announces FDA Clearance of Lactate Test
7. Adeona Announces HartLab Expansion Into Microbiology Testing Services
8. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
9. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
10. Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Par Pharmaceutical Announces the Resignation of Its Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 23, 2017  HealthMine surveys with 9,250 insured consumers ... health plan members want help from their plans in ... in their health, 2) help closing gaps in care, ... health and 5) relevant, real-time guidance. Meeting these needs ... costs. A Reason to Stay ...
(Date:3/24/2017)... , March 23, 2017  Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... Definitive Financing Commitment Term Sheet (the "Definitive Financing") ... group of the Company,s stockholders, who are referred ... in a Form 8-K filed with the Securities ...
(Date:3/24/2017)... 24, 2017 The Board of Directors of ... Report 2016 including the complete 2016 Annual Accounts with notes. ... Nordic Nanovector,s website in the section Investor Relations/Reports and presentations/Annual ... ... Kvåle, Chief Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... , ... According to a new study by NCPA Senior Fellow John R. ... rules Congress has directed the CBO to follow. The CBO itself previously recognized Obamacare ... it estimates a reduction in employer-based coverage due to the GOP reform, which is ...
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards for eating ... of disordered eating, announced today that the 2017 Symposium set a new attendance record ... countries converged on the Green Valley Resort in Las Vegas. , “We are ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents her Sacred ... 2017. This sacred and spiritual journey during the Summer Solstice will also ...
(Date:3/24/2017)... ... March 24, 2017 , ... As ... to create a communications platform that positions them as the go-to thought leader ... reinvented their online publication as an always-on, always-fresh news, views and advocacy engine, ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June ... ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She will present on: ... of cases litigated under ERISA involve claims for long-term disability benefits. This ...
Breaking Medicine News(10 mins):